Ghost authorship of research articles
The eternal question of authorship is in the frame in a News story in the current issue of Nature (452, 791; 2008), in which it is reported that thousands of of documents relating to Merck’s withdrawn painkiller rofecoxib (Vioxx) were were reviewed by medical researchers, and seem to show Merck’s extensive involvement in ghost-writing and ‘guest authorship’ of research and review papers. The results of the analysis are published by J. Ross et al. in the Journal of the American Medical Association (299, 1800–1812; 2008).
By omitting the names — or downgrading the involvement — of drug-industry writers, and adding the names of academics who were not substantially involved in a paper, the industry’s role in research may be concealed. And doctors may be misled over the independence of the work. For example, one of the Merck-held documents lists a number of clinical trials in which a Merck employee is to be author of the first draft of a manuscript. However, when these trials were published, in 16 of 20 of the articles an external academic is listed as first author. Merck denies these allegations.
See also Spoonful of Medicine, the blog of Nature Medicine.
There is further discussion of the JAMA article, and the implications for authorship credit, at Nature Network.
Comments
Merck denies these allegations.
Mandy Rice-Davies, innit?
Posted by: bill | April 21, 2008 05:51 PM